Press Releases



 
Press Releases
  Date Title View
Feb 26, 2018
REDWOOD CITY, Calif., Feb. 26, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced the U.S. commercial launch of the Oncotype DX® AR-V7 Nucleus Detect™ test. The first and only liquid biopsy test of its kind, the Oncotype DX AR-V7 Nucleus Detect test was developed by Epic Sciences to help prolong the lives of men wit...
PDF
Feb 22, 2018
REDWOOD CITY, Calif., Feb. 22, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, March 8 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2017 financial results. The call and webcast will follow the release of the fourth quarter and year...
PDF
Feb 5, 2018
REDWOOD CITY, Calif., Feb. 5, 2018 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of real-world clinical evidence demonstrating that use of the Oncotype DX® Genomic Prostate Score™ (GPS™) test resulted in significantly higher use of active surveillance at six and 12 months compared to no testing...
PDF
Dec 21, 2017
REDWOOD CITY, Calif., Dec. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 8, 2018 at 9:00 a.m. Pacific Ti...
PDF
Dec 11, 2017
REDWOOD CITY, Calif., Dec. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence Score® test and Oncotype DX® DCIS Score™ test in optimizing patient treatment across the breast cancer disease continuum. The data were ...
PDF
Dec 6, 2017
REDWOOD CITY, Calif., Dec. 6, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score™ (GPS™) test for their prostate cancer drug pipeline.  As part of the agreement, Genomic Health will test sam...
PDF
Nov 30, 2017
REDWOOD CITY, Calif., Nov. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX® studies at the 40th San Antonio Breast Cancer Symposium (SABCS), which is being held December 5-9, 2017. Presentation highlights include: Positive results from an international validation study...
PDF
Nov 28, 2017
REDWOOD CITY, Calif. and CLEVELAND, Nov. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licens...
PDF
Nov 21, 2017
REDWOOD CITY, Calif., Nov. 21, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, November 28, 2017 at 10:30 a.m. Eastern Time. To access the live and subsequently archived webcast of the presentation, go to the Inve...
PDF
Nov 8, 2017
REDWOOD CITY, Calif., Nov. 8, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2017. Total revenue was $83.8 million in the third quarter of 2017, compared with $82.3 million in the third quarter of 2016, an increase of 2 percent. Revenue was n...
PDF
FirstPrevious
2
...
NextLast